JNJ supply chain intelligence for Johnson & Johnson: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Johnson & Johnson (JNJ) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc. | 92% | Reciprocal relationship from PTGX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from PTGX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from PTGX gra… |
| GPK | Graphic Packaging Holding Company | 90% | Reciprocal relationship from GPK graph: Health/beauty customers include GlaxoSmithKline, Bayer, Johnson & Johnson, Abbott, Novartis, L’Oréal S.A., Proctor & Gamble, and Colgate. |
| IMERYS-TALC-AMERICA-INC | IMERYS-TALC-AMERICA-INC | 90% | In February 2019, the Company’s talc supplier, Imerys Talc America, Inc., and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys), filed voluntary pet… |
| ABBV | AbbVie Inc. | 85% | Reciprocal relationship from ABBV graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ABBV gra… |
| ANIK | Anika Therapeutics, Inc. | 85% | Reciprocal relationship from ANIK graph: l. The Company had no accrued warranties as of March 31, 2026, or December 31, 2025, and has no history of claims paid. 12 The Company is also involved from t… |
| CYPRUS-MINES-CORPORATION | CYPRUS-MINES-CORPORATION | 85% | In February 2021, Cyprus Mines Corporation (Cyprus), which sold certain talc mines and assets to Imerys, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the Delaware … |
| HBIO | Harvard Bioscience, Inc. | 85% | Reciprocal relationship from HBIO graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from HBIO graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from HBIO gra… |
| PCRX | Pacira BioSciences, Inc. | 85% | Reciprocal relationship from PCRX graph: 025, of which $ million are due in each of 2026 and 2027, $ million in 2028, and $ million in each of 2028 and 2029. The Company has $ million of other minimu… |
| ORGN | Origin Materials, Inc. | 80% | Reciprocal relationship from ORGN graph: HP Embalagens is a major Brazilian packaging company serving world-renowned brands such as Nestlé, Ferrero Rocher, 2 Natura, and Johnson & Johnson. |
| ACIU | AC Immune SA | 72% | Reciprocal relationship from ACIU graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ACIU gra… |
| ADGM | Adagio Medical Holdings, Inc. | 72% | Reciprocal relationship from ADGM graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ADGM graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ADGM gra… |
| ALC | Alcon Inc. | 72% | Reciprocal relationship from ALC graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ALC graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ALC graph:… |
| AMIX | Autonomix Medical, Inc. | 72% | Reciprocal relationship from AMIX graph: a limited number of regions or Key Opinion Leaders ("KOLs") to refine and optimize the commercial strategy prior to national and global deployment. Our commer… |
| AORT | Artivion, Inc. | 72% | Reciprocal relationship from AORT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from AORT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from AORT gra… |
| APLM | Apollomics, Inc. | 72% | Reciprocal relationship from APLM graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from APLM graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from APLM gra… |
| APT | Alpha Pro Tech, Ltd. | 72% | Reciprocal relationship from APT graph: Owens Corning and GAF for synthetic roof underlayment. Our major competitor in the medical and dental markets is Kimberly-Clark Corporation of Fort Worth, Texa… |
| ARGX | argenx SE | 72% | Reciprocal relationship from ARGX graph: lement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more ful… |
| ASML | ASML Holding N.V. | 72% | Reciprocal relationship from ASML graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ASML graph: hief Strategic Sourcing & Procurement Officer Term expires 2027 Executive Vic… |
| ATON | AlphaTON Capital Corp | 72% | Reciprocal relationship from ATON graph: ity of California, Santa Barbara. Robert Kramer, PhD has served as our Chief Scientific Officer since January 2019 . Dr. Kramer has over 33 years of experienc… |
| ATRA | Atara Biotherapeutics, Inc. | 72% | Reciprocal relationship from ATRA graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ATRA graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ATRA gra… |
| AURA | Aura Biosciences, Inc. | 72% | Reciprocal relationship from AURA graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from AURA graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from AURA gra… |
| AVBP | ArriVent BioPharma, Inc. | 72% | Reciprocal relationship from AVBP graph: therwise prefer to develop and market ourselves. We also face substantial competition from multiple sources, including large and specialty pharmaceutical and … |
| AVTX | Avalo Therapeutics, Inc. | 72% | Reciprocal relationship from AVTX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from AVTX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from AVTX gra… |
| BCAX | Bicara Therapeutics Inc. | 72% | Reciprocal relationship from BCAX graph: inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assurance that we would be able to access uninsu… |
| BLCO | Bausch + Lomb Corporation | 72% | Reciprocal relationship from BLCO graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from BLCO graph: itrust Generic Pricing Antitrust Litigation BHC and its subsidiaries, Oceansi… |
| BLLN | BillionToOne, Inc. | 72% | Reciprocal relationship from BLLN graph: l and criminal penalties, damages, fines, the curtailment or restructuring of operations and exclusion from participation in federal and state healthcare prog… |
| BLNK | Blink Charging Co. | 72% | Reciprocal relationship from BLNK graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from BLNK graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from BLNK gra… |
| BNR | Burning Rock Biotech Limited | 72% | Reciprocal relationship from BNR graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from BNR graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from BNR graph:… |
| BNRG | Brenmiller Energy Ltd | 72% | Reciprocal relationship from BNRG graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from BNRG graph: ce incubator in Israel established in partnership with Boston Scientific Corp… |
| CASI | CASI Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CASI graph: . Mr. Su has extensive experiences in the bioscience industry, and he has been a well-known investor in the life-science industry. Mr. Su is currently a partn… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-DEFENSE | USGOV-DEPARTMENT-OF-DEFENSE | 95% | USAspending awards from Department of Defense: $4,319,296 across 9 awards. SPE2D625F1LZG 4569174801!2.7MM/3.5MM VA-LCP ANKLE; SPE2D625F2EMD 4569301060!2.7MM/3.5MM VA-LCP ELBOW; SPE2D625F13XT 45668464… |
| KVUE | Kenvue Inc. | 92% | Reciprocal relationship from KVUE graph: The Company had the following balances and transactions with J&J and its affiliates, primarily in connection with the Tax Matters Agreement, Transition Servic… |
| TMCI | Treace Medical Concepts, Inc. | 80% | Reciprocal relationship from TMCI graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from TMCI graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from TMCI gra… |
| ACIU | AC Immune SA | 72% | Reciprocal relationship from ACIU graph: ave achieved and our goal of a close working relationship with the regulatory agencies, in particular the FDA and the EMA, are intended to facilitate expediti… |
| AMIX | Autonomix Medical, Inc. | 72% | Reciprocal relationship from AMIX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from AMIX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from AMIX gra… |
| APT | Alpha Pro Tech, Ltd. | 72% | Reciprocal relationship from APT graph: We manufacture, cut, warehouse and ship disposable protective apparel products and face shields in a 137,500 square foot facility in Nogales, Arizona. The majo… |
| CLGN | CollPlant Biotechnologies Ltd. | 72% | Reciprocal relationship from CLGN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CLGN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CLGN gra… |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: eline. We believe it has the capacity to support, in whole or in part, the manufacture and supply of product for certain of our current clinical programs with… |
| CVRX | CVRx, Inc. | 72% | Reciprocal relationship from CVRX graph: al device companies that have substantially greater financial, technical, sales and marketing resources than we do, such as Medtronic plc, Boston Scientific C… |
| CYCN | Cyclerion Therapeutics, Inc. | 72% | Reciprocal relationship from CYCN graph: rovides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity for both drugs and biologics… |
| ESTA | Establishment Labs Holdings Inc. | 72% | Reciprocal relationship from ESTA graph: Mentor Worldwide LLC (a division of Johnson & Johnson) and Allergan plc (acquired by AbbVie Inc.) have conducted large prospective clinical studies that start… |
| EVAX | Evaxion A/S | 72% | Reciprocal relationship from EVAX graph: ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. Prior to any out-licensing commercializati… |
| EVFM | Evofem Biosciences, Inc. | 72% | Reciprocal relationship from EVFM graph: umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any failure or future delay in the timely dev… |
| GLSI | Greenwich LifeSciences, Inc. | 72% | Reciprocal relationship from GLSI graph: duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may o… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from GNLX graph: d regulatory review of any drug we may develop from our product candidates, i… |
| GNMSF | Genmab A/S | 72% | Item 8 of this Report. Sales of the Company’s largest product, collectively DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), accounted for approximately 15.0% of the C… |
| GNMSF | Genmab A/S | 72% | Reciprocal relationship from GNMSF graph: Reciprocal relationship from JNJ graph: Item 8 of this Report. Sales of the Company’s largest product, collectively DARZALEX (daratumumab) and DARZALEX FASPR… |
| HBIO | Harvard Bioscience, Inc. | 72% | Reciprocal relationship from HBIO graph: . Army and CROs. Our pharmaceutical and biotechnology customers include pharmaceutical companies and research laboratories such as Abbott, Amgen, AstraZeneca,… |
| IMNM | Immunome, Inc. | 72% | Reciprocal relationship from IMNM graph: m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in … |
| IMVT | Immunovant, Inc. | 72% | Reciprocal relationship from IMVT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from IMVT graph: gulated, unapproved and off-label treatments. Even if a biosimilar product is… |
| IVF | INVO Fertility, Inc. | 72% | Reciprocal relationship from IVF graph: ls for our product candidates may be larger than it anticipates, enrollment in these clinical trials may be slower than it anticipate or may be lower than it a… |
| JANX | Janux Therapeutics, Inc. | 72% | Reciprocal relationship from JANX graph: ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in the co… |
| KYMR | Kymera Therapeutics, Inc. | 72% | Reciprocal relationship from KYMR graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from KYMR gra… |
| KYTX | Kyverna Therapeutics, Inc. | 72% | Reciprocal relationship from KYTX graph: a have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (i) any breach of our respective repr… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, i… |
| LEGN | Legend Biotech Corporation | 72% | xpense, net. Acquisition related costs before tax for the fiscal first quarter of 2026 were not material. Form 10-Q 25 Table of Contents The fair value of the assets acquired is $ 17.5 billion, which… |
| LENZ | LENZ Therapeutics, Inc. | 72% | Reciprocal relationship from LENZ graph: Good Manufacturing Practices (“cGMP”) regulatory guidelines. A Drug Master File (“DMF”) is on file with the FDA for the API. Commercial supply agreements have… |
| LNSR | LENSAR, Inc. | 72% | Reciprocal relationship from LNSR graph: zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and new markets. Our ALLY System currently … |
| LQDA | Liquidia Corporation | 72% | Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Trepr… |
| LTRN | Lantern Pharma Inc. | 72% | Reciprocal relationship from LTRN graph: the US, Australia, Canada, EU, China, and Japan. LP-300 Our portfolio directed to LP-300 consists of at least four families of owned patents. A more recent PC… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| JNJ-DEBT-6640 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2023-01-01. |
| JNJ-DEBT | Debt stack $45.8B | 90% | Market cache reports total debt of $45.8B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| JNJ-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 240,349,660; ownership 9.98%; value $58.5B; as of 2025-12-31. |
| JNJ-OWNER-BANK-OF-AMERICA-CORPORATION | Bank of America Corporation | 95% | 13F/ownership overlay lists Bank of America Corporation; shares held 28,419,787; ownership 1.18%; value $6.9B; as of 2025-09-30. |
| JNJ-OWNER-STATE-FARM-MUTUAL-AUTOMOBILE-INSURANCE-C | State Farm Mutual Automobile Insurance Co | 95% | 13F/ownership overlay lists State Farm Mutual Automobile Insurance Co; shares held 31,590,952; ownership 1.31%; value $7.7B; as of 2025-12-31. |
| JNJ-OWNER-MORGAN-STANLEY | Morgan Stanley | 95% | 13F/ownership overlay lists Morgan Stanley; shares held 48,231,667; ownership 2.00%; value $11.7B; as of 2025-09-30. |
| JNJ-OWNER-NORGES-BANK | NORGES BANK | 95% | 13F/ownership overlay lists NORGES BANK; shares held 33,459,884; ownership 1.39%; value $8.1B; as of 2025-12-31. |
| JNJ-OWNER-NORTHERN-TRUST-CORPORATION | Northern Trust Corporation | 95% | 13F/ownership overlay lists Northern Trust Corporation; shares held 29,972,551; ownership 1.24%; value $7.3B; as of 2025-09-30. |
| JNJ-OWNER-STATE-STREET-CORPORATION | State Street Corporation | 95% | 13F/ownership overlay lists State Street Corporation; shares held 132,206,061; ownership 5.49%; value $32.2B; as of 2025-09-30. |
| JNJ-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 208,781,159; ownership 8.67%; value $50.8B; as of 2025-12-31. |
| JNJ-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 57,953,747; ownership 2.41%; value $14.1B; as of 2025-12-31. |
| JNJ-OWNER-JPMORGAN-CHASE-CO | JPMORGAN CHASE & CO | 95% | 13F/ownership overlay lists JPMORGAN CHASE & CO; shares held 58,558,238; ownership 2.43%; value $14.3B; as of 2025-12-31. |
| JNJ-OWNER-JOHNSON-JOHNSON | JOHNSON & JOHNSON | 90% | 13F overlay lists JOHNSON & JOHNSON as top holder; 101 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| AGM | Federal Agricultural Mortgage Corporation | 100.00 | 2 | |
| DAVA | Endava plc | 100.00 | 2 | |
| BLNK | Blink Charging Co. | 100.00 | 1 | ['supplier'] |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| CRARF | Crédit Agricole S.A. | 100.00 | 2 | |
| BSX | Boston Scientific Corporation | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CTSH | Cognizant Technology Solutions Corporation | 100.00 | 2 | |
| AURX | Nuo Therapeutics, Inc. | 100.00 | 2 | |
| CVRX | CVRx, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BORAY | Bora Pharmaceuticals Co., Ltd. | 100.00 | 2 | |
| BPTH | Bio-Path Holdings, Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 100.00 | 1 | ['customer'] |
| BDTX | Black Diamond Therapeutics, Inc. | 100.00 | 2 |